BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-650-8895020
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees17
Next Earnings Date6/6/2019 (Estimated)
OptionableNot Optionable
Biopharmx (NYSEAMERICAN:BPMX) Frequently Asked Questions
What is Biopharmx's stock symbol?
Biopharmx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX."
When did Biopharmx's stock split? How did Biopharmx's stock split work?
Shares of Biopharmx reverse split before market open on Friday, April 26th 2019. The 1-25 reverse split was announced on Monday, April 15th 2019. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, April 25th 2019. An investor that had 100 shares of Biopharmx stock prior to the reverse split would have 4 shares after the split.
How were Biopharmx's earnings last quarter?
Biopharmx Corp (NYSEAMERICAN:BPMX) released its earnings results on Thursday, March, 14th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.02) by $0.01. The biotechnology company earned $0.01 million during the quarter. View Biopharmx's Earnings History.
When is Biopharmx's next earnings date?
What price target have analysts set for BPMX?
1 brokerages have issued 1 year target prices for Biopharmx's shares. Their predictions range from $0.40 to $0.40. On average, they anticipate Biopharmx's stock price to reach $0.40 in the next year. This suggests a possible upside of 502.4% from the stock's current price. View Analyst Price Targets for Biopharmx.
What is the consensus analysts' recommendation for Biopharmx?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biopharmx in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biopharmx.
Has Biopharmx been receiving favorable news coverage?
Media stories about BPMX stock have trended positive recently, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Biopharmx earned a coverage optimism score of 2.8 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the next several days.
Are investors shorting Biopharmx?
Biopharmx saw a increase in short interest in the month of March. As of March 29th, there was short interest totalling 5,463,101 shares, an increase of 85.5% from the March 15th total of 2,944,620 shares. Based on an average daily volume of 23,270,064 shares, the short-interest ratio is currently 0.2 days. Currently, 2.3% of the company's stock are sold short. View Biopharmx's Current Options Chain.
Who are some of Biopharmx's key competitors?
Some companies that are related to Biopharmx include ReNeuron Group (RENE), Orgenesis (ORGS), Promis Neurosciences (PMN), Bionomics (BNO), Tissue Regenix Group (TRX), Tiziana Life Sciences (TILS), OptiBiotix Health (OPTI), IntelGenx Technologies (IGX), Protalix Biotherapeutics (PLX), Pediapharm (PDP), Verona Pharma (VRP), Imugene (IMU), Actinogen Medical (ACW), Noxopharm (NOX) and Actinium Pharmaceuticals (ATNM).
What other stocks do shareholders of Biopharmx own?
Who are Biopharmx's key executives?
Biopharmx's management team includes the folowing people:
- Dr. David S. Tierney M.D., Pres, CEO, CFO and Director (Age 55)
- Dr. Kin Foong Chan, Exec. VP of Research & Technology (Age 45)
- Dr. José Zayas, Sr. VP of Operations
- Ms. Joyce Goto, VP, Chief Accounting Officer & Controller (Age 45)
- Ms. AnnaMarie Daniels, Exec. VP of Clinical & Regulatory Affairs
How do I buy shares of Biopharmx?
Shares of BPMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biopharmx's stock price today?
One share of BPMX stock can currently be purchased for approximately $0.0664.
How big of a company is Biopharmx?
Biopharmx has a market capitalization of $14.50 million. Biopharmx employs 17 workers across the globe.
What is Biopharmx's official website?
How can I contact Biopharmx?
Biopharmx's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020.
MarketBeat Community Rating for Biopharmx (NYSEAMERICAN BPMX)
MarketBeat's community ratings are surveys of what our community members think about Biopharmx and other stocks. Vote "Outperform" if you believe BPMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
